What outcome data do you view as most impactful to make treatment decisions regarding the use of PARP inhibitors in later line or recurrent ovarian cancer?  

Given the crossover that occurred in the various clinical trials and the potential for prolonged disease duration, how do you integrate OS, PFS, treatment free intervals, quality of life, or total cytotoxic chemotherapy exposure when considering treatment options?

Answer from: at Academic Institution